Sr. No.	Generic Name / Brand Name	Composition	on					Mfg. for	Reference
		Each film coated tablet contains					•		
	Cefixime &	Cefixime Trihydrate		IP				1	
	Cloxacillin	Eq. to Cefixime Anhydrus				100	mg		
0.1	Extended Release	Cloxacillin Sodium		IP			- 8		
01	Tablets	Eq. to Cloxacillin				500	mg	Our Self	
		(In Extended-Release Form)							
		Excipients				q.s.		1	
		Approved colour used in tablet					•	1	
		Each film coated tablet contains							
	Cefixime &	Cefixime Trihydrate		IP				1	
	Cloxacillin	Eq. to Cefixime Anhydrus				200	mg		
0.2	Extended Release	Cloxacillin Sodium		IP			Ŭ	0 6 16	
02	Tablets	Eq. to Cloxacillin				500	mg	Our Self	
		(In Extended-Release Form)					_		
		Excipients				q.s.			
		Approved colour used in tablet							
		Each uncoated tablet contains							
		Cefixime Trihydrate	IP					1	
	Cefixime,	Eq. to Cefixime Anhydrus			200		mg		
	Cloxacillin & Lactic Acid	Cloxacillin Sodium	IP					1	
03		Eq. to Cloxacillin			500		mg	Our Self	
	Bacillus Tablets	Lactic Acid Bacillus			90	m	illion		
						sı	ores		
		Excipients			q.s.			_	
		Approved colour used in tablet							
		Each film coated tablet contains					1		
	Cefixime &	Cefixime Trihydrate		IP		• • •			
	Dicloxacillin	Eq. to Cefixime Anhydrus		-		200	mg	_	
04	Extended-Release	Dicloxacillin Sodium		IP		500		Our Self	
	Tablets	Eq. to Dicloxacillin (In Extended-Release Form)				500	mg		
		Excipients				0.0		-	
		Approved colour used in tablet				q.s.		_	
		11							
		Each film coated tablet contains Cefixime Trihydrate		IP				-	
	Cefixime,	Eq. to Cefixime Anhydrus		11		200	mg		
	Cloxacillin &	Cloxacillin Sodium		ΙP	_	200	mg	-	
0.5	Lactic Acid	Eq. to Cloxacillin		11		500	mg	0 0 10	
05	Bacillus Tablets	(In Extended-Release Form)				200	1115	Our Self	
	Tablets	Lactic Acid Bacillus				90	million	1	
		P · · ·					spores	_	
		Excipients				q.s.			
		Approved colour used in tablet							1
	Coficient	Each uncoated dispersible tablet co	ontains					-	
	Cefixime and	Cefixime Trihydrate		ΙP	4	50	ma		
06	Potassium Clavulanate	Eq. to cefixime Potassium clavulanate diluted	_	IP	+)U	mg	Our Self	
00	Dispersible	Eq. to Clavulanic acid		11	31	.25	mg	Our Sen	
	Tablets	Excipients				i.S.	111g	-	
	1 401045	Approved colour used in tablet			1 9			1	
	_1							1	

Sr. No.	Generic Name / Brand Name	Compos	sition				Mfg. for	Reference
07	Cefpodoxime and Ofloxacin Dispersible Tablets	Each uncoated dispersible ta Cefpodoxime Proxetil Eq. to Anhydrus Cefpodoxim Ofloxacin Excipients Approved colour used in tab	ne	IP IP	100	mg mg	Our Self	
08	Cefixime and Potassium Clavulanate Dispersible Tablets	Each uncoated dispersible table Cefixime Trihydrate Eq. to Cefixime Potassium clavulanate diluted Eq. to clavulanic acid Excipients Approved colour used in table		IP IP	100 62.5 q.s.	mg mg	Our Self	
09	Cefixime and Potassium Clavulanate Tablets	Each film coated tablet contain Cefixime Trihydrate Eq. to Cefixime Potassium Clavulanate Diluted Eq. to Clavulanic Acid Excipients Approved colour used in table	1	II	200	mg	Our Self	
10	Cefixime Tablets IP	Each uncoated tablet contains Cefixime Trihydrate Eq. to Cefixime Excipients Approved colour used in table	et	IP	50 q.s.	mg	Our Self	
11	Cefixime Dispersible Tablets IP	Each uncoated dispersible table Cefixime Trihydrate Eq. to Cefixime Excipients Approved colour used in table		tains:	50 q.s.	mg	Our Self	
12	Cefixime Tablets	Each film coated tablet contain Cefixime Trihydrate Eq. to Cefixime Excipients Approved colour used in table	ns	II	400 q.s.	mg	Our Self	
13	Cefixime and Lactic Acid Bacillus Dispersible Tablets	Each uncoated dispersible table Cefixime Trihydrate Eq. to Anhydrus Cefixime Lactic Acid Bacillus Excipients Approved colour used in coatin	IP	100	m million s		Our Self	
14	Cefixime and Lactic Acid Bacillus Dispersible Tablets	Each uncoated dispersible table Cefixime Eq. to Anhydrous Cefixime Lactic Acid Bacillus Excipients Approved colour used in coatin	IP	200	m million s		Our Self	

Sr. No.	Generic Name / Brand Name	Composition	1				Mfg. for	Reference
		Each uncoated dispersible tablet con	tains:					
	Cefixime and	Cefixime trihydrate	IP					
1.5	Ofloxacin	Eq. to Cefixime			100	mg	O C -16	
15	Dispersible Tablets	Ofloxacin	IP		100	mg	Our Self	
		Excipients			q.s.			
		Approved colour used in tablet						
		Each film coated tablet contains						
		Cefixime Trihydrate	IP	ı				
16	Cefixime and	Eq. to Cefixime			100	mg	Over Calf	
16	Ofloxacin Tablets	Ofloxacin	IP	1	100	mg	Our Self	
		Excipients			q.s.			
		Approved colour used	•					
	~ ~	Each uncoated dispersible tablet con	tains:					
	Cefixime and	Cefixime trihydrate	IP					
17	Ofloxacin	Eq. to Cefixime			200	mg	O C - 16	
17	Dispersible Tablets	Ofloxacin	IP		200	mg	Our Self	
		Excipients			q.s.			
		Approved colour used in tablet	•		_			
		Each film coated tablet contains:						
	C C' ' 1	Cefixime trihydrate	IP					
	Cefixime and	Eq. to Cefixime			200	mg		
10	Ofloxacin Sustained	(As Sustained Release)					O C -16	
18	Release Tablets	Ofloxacin	IP		200	mg	Our Self	
		(As Sustained Release)						
		Excipients			q.s.			
		Approved colour used in tablet						
		Each uncoated dispersible tablet con						
	Cefixime,	Cefixime trihydrate	IP					
	Ofloxacin & Lactic Acid Bacilus	Eq. to Cefixime	TD -	20	^	mg		
19		Ofloxacin	<u>IP</u>	20		mg	Our Self	
	Tablets	Lactic Acid Bacillus		_6(illion		
		Excipients		a .		ores		
		Approved colour used in tablet		q.	5.			
		**						
		Each film coated tablet contains:	IP					
	Cefixime and	Cefixime trihydrate Eq. to Cefixime	IP		400	ma		
	Ofloxacin Sustained	(As Sustained Release)			400	mg		
20	Release Tablets	Ofloxacin	IP		400	mg	Our Self	
		(As Sustained Release)	111		400	mg		
		Excipients			q.s.			
		Approved colour used in tablet	_1		1	1		
		Each film coated tablet contains						
		Cefixime Trihydrate	IP	•			1	
	Cefixime,	Eq. to Cefixime Anhydrus			100	mg		
	Cloxacillin &	Cloxacillin Sodium	IP	•		<u> </u>	1	
21	Lactic Acid	Eq. to Cloxacillin			500	mg	Our Self	
21	Bacillus Tablets	(In Extended-Release Form)				J	Our Self	
	1 abiets	Lactic Acid Bacillus			60	million]	
						spores		
		Excipients			q.s.		1	
		Approved colour used in tablet						
22	Cefixime,	Each film coated tablet contains:-					Our Self	

Sr.	Generic Name / Brand Name	Compositi	on					Mfg. for	Reference
	Azithromycin &	Cefixime Trihydrate	IP)					
	Lactic Acid	Eq. to Cefixime Anhydrus			200		mg		
	Bacillus Tablets	Azithromycin Dihydrate	IP	, _					
		Eq. to Azithromycin Anhydrous	+		250		mg		
		Lactic Acid Bacillus			-60	n	nillion	1	
							pores		
		Excipients			q.s.		•		_
		Approved colour used in tablet.							
		Each uncoated tablet contains: -							
		Cefixime Trihydrate	IP	•					
	0 5 :	Eq. to Cefixime Anhydrus			200	_	<u>mg</u>		
	Cefixime,	Azithromycin Dihydrate	IP	,					
23	Azithromycin &	Eq. to Azithromycin Anhydrous	\top		500		mg	Our Self	
	Lactic Acid Bacillus Tablets	Lactic Acid Baeillus			60	m	nillion		
	Bacilius Tablets					S	pores		
		Excipients			q.s.				
		Approved colour used in tablet.		•					
		Each uncoated sustained release ta	blet	cont	ains				
		Cefixime Trihydrate		IP]	
		Eq. to Cefixime			400)	mg		
	Cefixime and	(As Sustained Release)							
24	Moxifloxacin	Moxifloxacin Hydrochloride		IP				Our Self	
	Sustained Tablets	Eq. to Moxifloxacin			400)	mg		
		(As Sustained Release)							
		Excipients			q.s				
		Approved colour used in tablet							
		Each 5ml after reconstitution conta	ins:						
	Cefixime for Oral	Cefixime Trihydrate		ΙP					
25	Suspension IP	Eq. to Cefixime			50	1	mg	Our Self	
	_	In a palatable suspension base			q.s				
		Approved colour used							
		Each 5ml after reconstitution con-	tains	:					
	Cefixime for Oral	Cefixime Trihydrate		ΙP					
26	Suspension IP	Eq. to Cefixime			100)	mg	Our Self	
	•	In a palatable suspension base			q.s				
		Approved colour used							
	Cefixime and	Each 5 ml of reconstituted suspens	ion (conta	ains				
	Ofloxacin Oral	Cefixime Trihydrate		IP					
27	Suspension	Eq. to Anhydrous Cefixime			5	0	mg	Our Self	
	1	Ofloxacin		ΙP	5	0	mg		
		In a palatable suspension base			q.s				
		Each 5 ml of reconstituted suspens	ion (conta					
	Cefixime and	Cefixime Trihydrate IP							
28	Ofloxacin Oral	Eq. to Anhydrous Cefixime			1	00	mg	Our Self	
	Suspension	Ofloxacin		IP		00	mg		
		In a palatable suspension base			q.s				
	l .	<u>, , , , , , , , , , , , , , , , , , , </u>			1 1		1		

Sr. No.	Generic Name / Brand Name	Comp	Composition						
		Each 5 ml of reconstituted sus	pensio	on cont	ains		•		
	Cefixime and	Cefixime Trihydrate	1	IP					
29	Ofloxacin Oral	Eq. to Anhydrous Cefixime			200	mg	Our Self		
	Suspension	Ofloxacin		IP	200	mg			
	•	In a palatable suspension base	;		q.s.				
		Each 5 ml of reconstituted sus	pensio	on cont	ains				
	Cefixime and	Cefixime Trihydrate	IP						
20	Lactic Acid	Eq. to Cefixime		50	mg	5	0 0 16		
30	Bacillus Oral	Lactic Acid Bacillus		60	million s	pores	Our Self		
	Suspension	In a palatable suspension base	q.s.						
		Approved colour used							
		Each 5 ml of reconstituted sus	pensio	on cont	ains				
	C C	Cefixime Trihydrate	ΙP						
	Cefixime and	Eq. to Cefixime		100	mg				
31	Lactic Acid Bacillus Oral	Lactic Acid Bacillus		60	million s	pores	Our Self		
	Suspension	In a palatable suspension	q.s.						
	Buspension	base							
		Approved colour used							
	Cefixime and		ach 5ml reconstituted suspension contains:						
	Potassium	Cefixime Trihydrate		IP					
	Clavulanate Oral	Eq. to Cefixime			50	mg			
32	Suspension	Potassium Clavulanate Diluted		IP			Our Self		
	Базрензіон	Eq. to Clavulanic Acid			31.25	mg	4		
		In a palatable suspension base					_		
		Approved colour used							
		Each 5 ml of reconstituted sus	pensio		tains:				
	Cefixime &	Cefixime Trihydrate		IP	100				
22	Potassium	Eq. to Cefixime		-115	100-	mg	0 0 10		
33	Clavulanate Oral	Potassium clavulanate diluted	\langle	TP_	28.5		Our Self		
	Suspension IP	Eq. to clavulanic acid				mg			
		Excipients Approved colour used.			q.s.				
		Each 5 ml of reconstituted sus	noncie	on cont	oine		1		
		Cefixime Trihydrate	pensi	IP	anis		╡		
	Cefixime and	Eq. to Cefixime		111	100	mg			
34	Potassium	Potassium clavulanate diluted		IP	100	mg	Our Self		
34	Clavulanate Oral	Eq. to Clavulanic acid		11	62.5	mg	Our Ben		
	Suspension	In a palatable suspension base	;		q.s.	8	1		
		Approved colour used			1 4.5.		1		
		Each Film coated tablet conta	ins						
	Cefuroxime Axetil	Cefuroxime Axetil		IP			1		
35	Tablets IP	Eq. to Cefuroxime			250	mg	Our Self		
		Excipients			q.s.				
		Approved colour used in table	1						
		Each Film coated tablet conta							
	Cefuroxime Axetil	Cefuroxime Axetil		IP			1		
36	Tablets IP	Eq. to Cefuroxime		1	500	mg	Our Self		
		Excipients			q.s.				
		Approved colour used in table	et	ı	1		1		
L	I .	TT TOTAL BOOK IN MOTO					1	1	

Sr. No.	Generic Name / Brand Name	Composition	on					Mfg. for	Reference
		Each film coated tablet contains							
	Cefuroxime Axetil	Cefuroxime Axetil		ΙP					
	and Potassium	Eq. to Cefuroxime			25	0	mg		
37	Clavulanate Tablets	Potassium Clavulanate Diluted		IP				Our Self	
	IP	Eq. to Clavulanic Acid			12	25	mg		
		Excipients			q.s				
		Approved colour used in tablet							
	G 6 . A .!1	Each film coated tablet contains							
	Cefuroxime Axetil	Cefuroxime Axetil		IP					
	and Potassium Clavulanate Tablets	Eq. to Cefuroxime	5			0	mg		
38	IP	Potassium Clavulanate Diluted		IP				Our Self	
	11	Eq. to Clavulanic Acid			12	5	mg		
		Excipients			q.s	S.			
		Approved colour used in tablet	olet						
		Each 5 ml of reconstituted suspens		onta	ins:				
	Cefuroxime &	Cefuroxime Axetil	IP						
	Potassium	Eq. to Cefuroxime		_	_125_		mg		
39	Clavulanate Oral	Potassium Clavulanate Diluted	IP.		-20 -			Our Self	
	Suspension IP	Eq. to Clavulanic Acid			28.5	\vdash	mg		
		In a palatable suspension base			q.s.				
			approved colour used.						
		Each 5 ml of reconstituted suspens		onta	ins:	1			
	Cefuroxime &	Cefuroxime Axetil	IP		250				
40	Potassium	Eq. to Cefuroxime	10		250		mg	0 0 10	
40	Clavulanate Oral	Potassium Clavulanate Diluted	IP_		57			Our Self	
	Suspension IP	Eq. to Clavulanic Acid In a palatable suspension base					mg		
		Approved colour used.			q.s.				
		Each 5 ml of reconstituted suspens	ion C	onto	ing				
	Cefuroxime Axetil	Cefuroxime Axetil	Ion C		ms.				
	and Potassium	Eq. to Cefuroxime	11		125		mg		
41	Clavulanate Oral	Potassium Clavulanate Diluted	II)	123		mg	Our Self	
71	Suspension	Eq. to Clavulanic Acid	1		31.25	5	mg	Our Ben	
	Suspension	In a palatable suspension base			q.s.	_	8		
		Approved colour used	l						
		Each film coated tablet contains	ı						
	Cefuroxime	Cefuroxime Axetil	IP						
	Axetil and	Eq. to Cefuroxime	111		125	m	σ		
42	Potassium	Potassium Clavulanate Diluted	IP		123	m	<u> </u>	Our Self	
42	Clavulanate	Eq to Clavulanic Acid	IF		31.25	m	œ	Our Sen	
	Tablets IP	1				m	<u> </u>		
	1 autets if	Excipients Approved colour yeard in tablet			q.s.				
		Approved colour used in tablet							
	Cefuroxime Axetil	Each film coated tablet contains	Τ,	· · ·	1				
	and Potassium	Cefuroxime Axetil		IΡ		-			
42	Clavulanate Tablets	Eq. to Cefuroxime	-	IP	25	ou_	mg	O C 10	
43	IP	Potassium Clavulanate Diluted Eq. to Clavulanic Acid		ır	60	2.5	ma	Our Self	
		Excipients					mg		
		Approved colour used in tablet			q.	ь.			
	<u> </u>	ripproved colour used in tablet							

Sr. No.	Generic Name / Brand Name	Composition		Mfg. for	Reference				
	~	Each 5ml reconstituted suspension co	ontains:						
	Cefuroxime Axetil	Cefuroxime Axetil	IP			1			
44	Oral	Eq. to Cefuroxime		125	mg	O C -16			
	Suspension	In a palatable suspension base		q.s.		Our Self			
		Approved colour used	•			1			
		Each Uncoated Dispersible tablet co	ntains						
	Cefpodoxime and	Cefpodoxime Proxetil	IP			1			
	Potassium	Eq to Anhydrous Cefpodoxime		50	mg				
45	Clavulanate	Potassium Clavulanate Diluted	IP			Our Self			
	Dispersible Tablets	Eq. to Clavulanic Acid		31.25	mg	_			
		Excipients		q.s.					
		Approved colour used in tablet							
		Each uncoated dispersible tablet con	tains						
		Cefpodoxime proxetil	IP]			
	Cefpodoxime and	Eq. to anhydrous cefpodoxime		100	mg				
46	Potassium	Potassium clavulanate diluted	IP			Our Self			
	Clavulanate	Eq. to clavulanic acid		62.5	mg				
	Dispersible Tablets	Excipients		q.s.]			
		Approved colour used in tablet			I	1			
		Each film coated tablet contains							
	Cefpodoxime and	Cefpodoxime Proxetil	IP			1			
	Potassium	Eq. to Cefpodoxime		100	mg				
47	Clavulanate Tablets	Potassium Clavulanate Diluted	IP			Our Self			
		Eq. to Clavulanic Acid		62.5	mg				
		Excipients		q.s.					
		Approved colour used in tablet							
		Each film coated tablet contains							
	Cefpodoxime and	Cefpodoxime Proxetil	IP						
	Potassium	Eq. to Anhydrous Cefpodoxime	-	200	mg				
48	Clavulanate Tablets	Potassium Clavulanate Diluted	IP	l l	,	Our Self			
		Eq. to Clavulanic Acid		125		-			
		Excipients Approved colour used in tablet		q.s.		-			
		Each uncoated dispersible tablet con	4.1						
	Cefpodoxime	Cefpodoxime Proxetil	IP						
49	Proxetil Dispersible	Eq. to Cefpodoxime	117	50	mg	Our Self			
47	Tablets	Excipients		q.s.	mg	Our Sen			
		Approved colour used in tablet		4.5.					
	Cefpodoxime	Each uncoated dispersible tablet cor	ntaine						
	Proxetil	Cefpodoxime Proxetil	IP						
5 0	Dispersible Tablets	Eq. to Cefpodoxime	**	100	mg	0 6 16			
50	100 mg	Excipients		q.s.	5	Our Self			
		Approved colour used in tablet							
	Cofnodovima	Each Uncoated tablet contains							
	Cefpodoxime Tablets IP	Cefpodoxime Proxetil	IP						
51	1 autots IF	Eq. to Cefpodoxime		100	mg	Our Self			
		Excipients		q.s.					
		Approved colour used in tablet							

Sr. No.	Generic Name / Brand Name	Composition	Composition						
52	Cefpodoxime Tablets IP	Each Uncoated tablet contains Cefpodoxime Proxetil Eq. to Cefpodoxime Excipients Approved colour used in tablet	II	P	200 q.s.	mg	Our Self		
53	Cefpodoxime Tablets IP	Each film coated tablet contains Cefpodoxime Proxetil Eq. to Cefpodoxime Excipients Approved colour used in tablet	II	P	200 q.s.	mg	Our Self		
54	Cefpodoxime Proxetil Dispersible Tablets	Each uncoated dispersible tablet cor Cefpodoxime Proxetil Eq. to Cefpodoxime Excipients Approved colour used in tablet	ntains IP		200 q.s.	mg	Our Self		
		Each Film coated sustained release t							
55	Cefpodoxime Proxetil SR Tablets	Cefpodoxime Proxetil Eq. to Cefpodoxime Excipients		IP	200 q.s.	mg	Our Self		
		Approved colour used in tablet							
56	Cefpodoxime Proxetil SR Tablets	Each Film coated sustained release to Cefpodoxime Proxetil Eq. to Cefpodoxime Excipients	tablet	IP	400 q.s		Our Self		
		Approved colour used in tablet							
57	Cefpodoxime & Potassium Clavulanate Oral Suspension IP	Each 5 ml of reconstituted suspension Cefpodoxime Proxetil IP Eq to Cefpodoxime Potassium clavulanate diluted Eq. to clavulanic acid Excipients	on Co IP IP	28	8.5 .s.	mg	Our Self		
		Approved colour used.		1					
58	Cefpodoxime and Potassium Clavulanate Oral Suspension	Each 5ml reconstituted suspension of Cefpodoxime Proxetil Eq. to Anhydrous Cefpodoxime Potassium Clavulanate Diluted Eq. to Clavulanic Acid In a palatable suspension base Approved colour used	IP IP		50 31.25	mg mg	Our Self		
		Each 5 ml of reconstituted suspension							
59	Cefpodoxime & Potassium Clavulanate Oral Suspension IP	Cefpodoxime Proxetil IP Eq to Cefpodoxime Potassium clavulanate diluted Eq. to clavulanic acid Excipients	IP IP	28	8.5 .s.	mg mg	Our Self		
		Approved colour used.							

Sr. No.	Generic Name / Brand Name	Composition	1				Mfg. for	Reference
		Each film coated tablet contains						· · · · · · · · · · · · · · · · · · ·
		Cefpodoxime Proxetil	IP					
	Cefpodoxime &	Eq. to Cefpodoxime			100	mg		
60	Dicloxacillin (ER)	Dicloxacillin Sodium	IP				Our Self	
	Tablets	Eq. to Dicloxacillin (As ER)			500	mg		
		Excipients		q].S.			
		Approved colour used in tablet						
		Each film coated tablet contains						
		Cefpodoxime Proxetil	IP					
	Cefpodoxime &	Eq. to Cefpodoxime			200	mg		
61	Dicloxacillin (ER)	Dicloxacillin Sodium	IP				Our Self	
	Tablets	Eq. to Dicloxacillin (As ER)			500	mg		
		Excipients			q.s.		7	
		Approved colour used in tablet	ı					
	Cofnodovima and	Each film coated tablet contains Cefpodoxime Proxetil	IP)			-	
	Cefpodoxime and Ofloxacin Tablets	Eq. to Cefpodoxime	11		100	mg		
62	Onoxaciii Tablets	Ofloxacin	IP)	100	mg	Our Self	
		Excipients	- 11		q.s.	mg	_	
		Approved colour used in tablet			4.5.		=	
		<u> </u>						
		Each film coated tablet contains	- T-		1		_	
	Cefpodoxime and Ofloxacin Tablets	Cefpodoxime Proxetil	1	P	200			
63		Eq. to Cefpodoxime	Т	D	200	mg	Our Self	
		Ofloxacin	1	P	200	mg	_	
		Excipients			q.s.			
		Approved colour used in tablet						
		Each uncoated dispersible tablet contains				_		
	Cephalexin	Cephalexin	IP		105			
64	Dispersible Tablets	Eq. to Anhydrous Cephalexin				mg	Our Self	
	1	Excipients			q.s.		_	
		Approved colour used in tablet						
	Cephalexin	Each Uncoated tablet contains	1					
	Tablets IP	Cephalexin	IP					
65	1 autets 11	Eq. to Anhydrous Cephalexin			250	mg	Our Self	
		Excipients			q.s.			
		Approved colour used in tablet						
		Each uncoated dispersible tablet co	ntains					
		Cephalexin	II	2				
66	Cephalexin	Eq. to Anhydrous Cephalexin			250	mg	Our Self	
	Dispersible Tablets	Excipients			q.s.			
		Approved colour used in tablet	·					
	Fach 5 ml of reconstituted suspension Contains:							
	Cephalexin Oral	Cephalexin	IP	III				
67	Suspension IP	Eq. to Anhydrous Cephalexin			125	mg	Our Self	
	•	In a palatable suspension base		-	q.s.	-0		
	<u> </u>	Each 5 ml of reconstituted suspens	ion Co	nta				
	Cephalexin Oral	Cephalexin		Contains:			Our Self	
68	Suspension IP	Eq. to Anhydrous Cephalexin		**	250	mg	Jui 5011	
		In a palatable suspension base	+		q.s.	1115		
	1	in a paratable suspension base			4.5.			

Sr. No.	Generic Name / Brand Name	Composition				Mfg. for	Reference
110.		Fach 5 ml of accountituted assessments		~			
	Cefadroxil and Potassium	Each 5 ml of reconstituted suspension c Cefadroxil Monohydrate	IP	.S			
	Clavulanate Oral	Eq. to Anhydrous Cefadroxil	IF	250	ma		
69	Suspension	Potassium Clavulanate Diluted	IP	230	mg	Our Self	
	Suspension	Eq. to Clavulanic Acid	11	62.5	mg		
		In a palatable suspension base		02.3	mg		
		Each uncoated dispersible tablet contain					
	Cefadroxil and	Cefadroxil Monohydrate	IP				
	Potassium	Eq. to Anhydrous Cefadroxil	11	250	mg		
70	Clavulanate	Potassium Clavulanate Diluted	IP	230	mg	Our Self	
, ,	Dispersible Tablets	Eq. to Clavulanic Acid	1	62.5	mg	our sen	
		Excipients		q.s.	8		
		Approved colour used in tablet		1	I		
		Each film coated tablet contains:					
	Cefadroxil and	Cefadroxil Monohydrate	IP				
	Potassium	Eq. to Anhydrous Cefadroxil	1	500	mg		
71	Clavulanate Tablets	Potassium Clavulanate Diluted	IP		8	Our Self	
		Eq. to Clavulanic Acid		125	mg		
		Excipients		q.s.			
		Approved colour used in tablet	•	_			
		Each Film coated tablet Contains:					
72	Cefdinir Tablets	Cefdinir	USF	300	mg	Our Self	
		Excipients		q.s			
		Approved colour used		1			
		Each film coated tablet contains:					
	200	Faropenem Sodium					
73	Faropenem 200 mg	Eq. to Faropenem		200	mg	Our Self	
	Tablet	Excipients		q.s.			
		Approved colour used in tablet					
		Each film coated tablet contains:					
	Foronom 200 ma	Faropenem Sodium]	
74	Faropenem 300 mg Tablet	Eq. to Faropenem		300	mg	Our Self	
	Tablet	Excipients		q.s.		<u> </u>	
		Approved colour used in tablet			·		